Sage Therapeutics, Inc.
SAGE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $67 | $45 | $81 | $100 |
| Short-Term Investments | $298 | $379 | $423 | $470 |
| Receivables | $27 | $11 | $9 | $15 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $17 | $20 | $18 | $21 |
| Total Curr. Assets | $409 | $454 | $531 | $605 |
| Property Plant & Equip (Net) | $11 | $11 | $12 | $12 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $1 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $4 | $4 | $5 |
| Total NC Assets | $14 | $15 | $16 | $17 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $423 | $470 | $547 | $622 |
| Liabilities | – | – | – | – |
| Payables | $1 | $5 | $13 | $7 |
| Short-Term Debt | $2 | $2 | $1 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $42 | $43 | $58 | $53 |
| Total Curr. Liab. | $45 | $50 | $72 | $60 |
| LT Debt | $10 | $10 | $11 | $10 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $10 | $10 | $11 | $10 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $10 | $12 | $12 | $10 |
| Total Liabilities | $54 | $60 | $82 | $71 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$3,082 | -$3,033 | -$2,970 | -$2,875 |
| AOCI | $0 | $0 | $0 | $1 |
| Other Equity | $3,451 | $3,442 | $3,435 | $3,425 |
| Total Equity | $369 | $410 | $465 | $552 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $423 | $470 | $547 | $622 |
| Net Debt | -$56 | -$33 | -$69 | -$89 |